



**GO NORTE  
INTERNATIONAL  
GU DEBATES**



**OCTOBER 5<sup>th</sup>-6<sup>th</sup>, 2023**

# **PERIOPERATIVE TREATMENT IN GU ONCOLOGY: THE DEBATE IS OPEN**

## **THE CASE OF BLADDER CANCER**



## CASE 1

- 72 yo gentleman with no significant comorbidities
- Diagnosed in a TURBT of a high-grade (G3) urothelial carcinoma pT2
- In a pre-surgical MRI the staging was cT3 because of peri-bladder fat involvement
- ddMAC x 4 cycles were offered as neoadjuvant treatment
- Radical cystectomy was performed in time with no major complications
- Pathology report revealed a high-grade (G3) pT1 N0 Mx residual tumor (downstaging)  
PDL1 CPS 14



## CASE 1 | QUESTION: What would you do now?

1. Nivolumab adjuvant for 1 year
2. GEMCIS x 3 cycles if residual renal function is above 50 ml/min
3. Nothing



## CASE 2

- 63 yo lady with no significant comorbidities
- Diagnosed of a mass in the left distal ureter
- Radical nephro-ureterectomy was performed upfront
- Creatinine clearance after surgery was 56 ml/min
- Pathology report revealed a high-grade (G3) pT3 N0 Mx
- PDL1 CPS 34



## CASE 2 | QUESTION: What would you do now?

1. Nivolumab adjuvant for 1 year
2. GEMCIS x 3-4 cycles
3. GEMCARBO x 3-4 cycles
4. Nothing